fda semaglutide compounding warning november 2025 Beyond the Headlines: Letters to GLP-1 Compounders FDA Warns on Certain Forms

Experts Encourage Use of GLP-1s in Cardiovascular Care Julia Bonavitacola Laura Joszt, MA Key Takeaways GLP-1 inhibitors significantly reduce cardiovascular events and mortality, with promising results in weight reduction and heart failure symptom improvement

The Influence and Mechanism of GLP-1 RAs in Improving Diabetic Cardiopathy At present, diabetic cardiopathy is acknowledged as a condition defined by cardiac dysfunction resulting from aberrant cardiac structure and function in diabetic patients, irrespective of other cardiac risk factors

Importantly, NAC supplementation significantly increased the clinical pregnancy rate per OI cycle (30.99% vs

2007 Apr;292(4):L813-23

Either way, the goal isnt restriction

Gallbladder considerations: Full-dose GLP-1 therapy is associated with increased gallbladder events